{"commentary":{"count":56,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":23,"youtube":18,"podcast":15},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02003222\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT02003222","nct_id":"NCT02003222","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02003222. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"See Detailed Description","label":"Arm I (blinatumomab, chemotherapy)","type":"EXPERIMENTAL"},{"description":"See Detailed Description","label":"Arm II (chemotherapy)","type":"ACTIVE_COMPARATOR"}],"collaborators":["Canadian Cancer Trials Group"],"completion_date":{"date":"2027-02-25","type":"ESTIMATED"},"conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative"],"enrollment":{"count":488,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Allogeneic Hematopoietic Stem Cell Transplantation","type":"PROCEDURE"},{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Blinatumomab","type":"BIOLOGICAL"},{"name":"Bone Marrow Aspiration","type":"PROCEDURE"},{"name":"Bone Marrow Biopsy","type":"PROCEDURE"},{"name":"Cyclophosphamide","type":"DRUG"},{"name":"Cytarabine","type":"DRUG"},{"name":"Daunorubicin","type":"DRUG"},{"name":"Daunorubicin Hydrochloride","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"},{"name":"Etoposide","type":"DRUG"},{"name":"Leucovorin Calcium","type":"DRUG"},{"name":"Lumbar Puncture","type":"PROCEDURE"},{"name":"Mercaptopurine","type":"DRUG"},{"name":"Methotrexate","type":"DRUG"},{"name":"Pegaspargase","type":"DRUG"},{"name":"Prednisone","type":"DRUG"},{"name":"Rituximab","type":"BIOLOGICAL"},{"name":"Vincristine","type":"DRUG"},{"name":"Vincristine Sulfate","type":"DRUG"},{"name":"X-Ray Imaging","type":"PROCEDURE"}],"last_update":"2026-09-21","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2023-06-23","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS) Among Patients Who Were MRD Negative After Induction and Intensification Chemotherapy","timeFrame":"Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 5 years"}],"references":[{"citation":"Zhong X, Roberts KG, Wei H, Sun Z, Montefiori LE, Kumar A, Iacobucci I, Baviskar P, Gao Q, Polonen P, Pruett-Miller SM, Schreiber RM, Chang TC, Zhang W, Lei S, Rampersaud E, Fan Y, Wu G, Mattison RJ, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Wieduwilt MJ, Abou Mourad Y, Shami PJ, Baer MR, Asch AS, O'Dwyer KM, Hall A, Liedtke M, Bergeron J, Wood BL, Pratz KW, Dinner SN, Frey NV, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, Podoltsev NA, DeAngelo DJ, Patel S, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave RR, Sharon E, Little RF, Erba HP, Stone RM, Tallman MS, Yang JJ, Luger SM, Paietta E, Litzow MR, Mullighan CG. Genomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study. Blood. 2026 Oct 5:blood.2026033793. doi: 10.1182/blood.2026033793. Online ahead of print.","pmid":"42832396","type":"DERIVED"},{"citation":"Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Wieduwilt MJ, Liedtke M, Bergeron J, Wood BL, Zhao Y, Wu G, Chang TC, Zhang W, Pratz KW, Dinner SN, Frey N, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, DeAngelo DJ, Patel SB, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave RR, Sharon E, Little RF, Erba HP, Stone RM, Luger SM, Mullighan CG, Tallman MS. Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2024 Jul 25;391(4):320-333. doi: 10.1056/NEJMoa2312948.","pmid":"39047240","type":"DERIVED"},{"citation":"Seftel MD. Hyper-CVAD: a regimen for all seasons. Lancet Haematol. 2020 Jul;7(7):e501-e502. doi: 10.1016/S2352-3026(20)30179-4. No abstract available.","pmid":"32589970","type":"DERIVED"}],"start_date":{"date":"2014-05-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","url":"https://clinicaltrials.gov/study/NCT02003222"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02003222"}